

Resource Summary Report

Generated by [RRID](#) on Aug 30, 2026

NCI-H596

RRID:CVCL_1571

Type: Cell Line

Proper Citation

RRID:CVCL_1571

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1571

Proper Citation: RRID:CVCL_1571

Description: Cell line NCI-H596 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung adenosquamous carcinoma

Defining Citation: [PMID:1311061](#), [PMID:1563005](#), [PMID:7972006](#), [PMID:8806092](#), [PMID:8806101](#), [PMID:10536175](#), [PMID:11005564](#), [PMID:11030152](#), [PMID:19472407](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26361996](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: PI3K genetic alteration cell panel (ATCC TCP-1028)., Part of: MD Anderson Cell Lines Project., Part of: EGFR genetic alteration cell panel (ATCC TCP-1027)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H596

Synonyms: H596, H-596, NCI-HUT-596, NCIH596

Cross References: BTO:BTO_0002209, CLO:CLO_0008098, EFO:EFO_0006694, AddexBio:C0016020/4974, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-178, BioSample:SAMN03472805, BioSample:SAMN10988026,

cancer cell lines: CVCL_1571, CCRID:1101HUM-PUMC000257, Cell_Model_Passport:SIDM01127, ChEMBL-Cells:ChEMBL3307791, ChEMBL-Targets:ChEMBL612256, CLS:305277, Cosmic:687828, Cosmic:801586, Cosmic:844832, Cosmic:876226, Cosmic:897514, Cosmic:908459, Cosmic:918001, Cosmic:929973, Cosmic:934548, Cosmic:1067762, Cosmic:1146920, Cosmic:1188588, Cosmic:1219079, Cosmic:1239917, Cosmic:1694668, Cosmic:1802293, Cosmic:1995584, Cosmic:2125254, Cosmic:2647637, Cosmic:2664125, Cosmic:2668268, Cosmic:2668324, Cosmic:2772156, Cosmic-CLP:908459, DepMap:ACH-000628, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:908459, GEO:GSM206496, GEO:GSM274796, GEO:GSM274829, GEO:GSM434310, GEO:GSM784243, GEO:GSM794294, GEO:GSM817075, GEO:GSM844656, GEO:GSM887437, GEO:GSM888517, GEO:GSM1374756, GEO:GSM1374757, GEO:GSM1670251, GEO:GSM2807225, GEO:GSM2807226, IARC_TP53:521, IGRhCellID:NCIH596, KCLB:90596, LiGeA:CCLE_201, LINCS_LDP:LCL-1786, PharmacDB:NCIH596_1121_2019, PRIDE:PXD002556, PRIDE:PXD030304, Progenetix:CVCL_1571, PubChem_Cell_line:CVCL_1571, Wikidata:Q54908082

ID: CVCL_1571

Record Creation Time: 20220427T220840+0000

Record Last Update: 20260829T234734+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H596.

No alerts have been found for NCI-H596.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Li Y, et al. (2026) Mitigating tumor heterogeneity in lung Cancer: A dual-targeted NIR-II imaging strategy for accurate tumor localization and intraoperative navigation. Cancer letters, 640, 218241.

Zhou Y, et al. (2026) Distinct Regulation of the ARF and TAp73 Tumor Suppressor Genes by the Transcription Factor E2F1 Enables Discrimination of Cancer Cells from Normal Growing Cells. Cells, 15(1).

Park J, et al. (2025) MYC plus class IIa HDAC inhibition drives mitochondrial dysfunction in non-small cell lung cancer. Cell reports, 44(6), 115722.

Sun F, et al. (2024) Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2. *eLife*, 12.

Ghezzi C, et al. (2023) Pacritinib inhibits glucose consumption in squamous cell lung cancer cells by targeting FLT3. *Scientific reports*, 13(1), 1442.

Fernandes M, et al. (2023) MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanized HGF knock-in mice. *Molecular oncology*.

Gozgit JM, et al. (2021) PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity. *Cancer cell*, 39(9), 1214.

Puray-Chavez M, et al. (2021) Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell. *Cell reports*, 36(2), 109364.

Yenerall P, et al. (2020) RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. *Cell chemical biology*, 27(1), 105.

Takahashi N, et al. (2020) 3D Culture Models with CRISPR Screens Reveal Hyperactive NRF2 as a Prerequisite for Spheroid Formation via Regulation of Proliferation and Ferroptosis. *Molecular cell*, 80(5), 828.

Momcilovic M, et al. (2018) The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma. *Cancer cell*, 33(5), 905.

Lin R, et al. (2018) The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells. *Molecular cell*, 69(6), 923.

Topper MJ, et al. (2017) Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. *Cell*, 171(6), 1284.